Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.

Publication Type:

Journal Article

Authors:

Freedman, Andrew N; Yu, Binbing; Gail, Mitchell H; Costantino, Joseph P; Graubard, Barry I; Vogel, Victor G; Anderson, Garnet L; McCaskill-Stevens, Worta

Source:

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 29, Issue 17, p.2327-33 (2011)

Keywords:

2011, Aged, Breast Neoplasms, Chemoprevention, Clinical Trials as Topic, Estrogen Antagonists, Female, Hispanic Americans, Humans, Middle Aged, Public Health Sciences Division, RALOXIFENE, Tamoxifen

Abstract:

The Study of Tamoxifen and Raloxifene (STAR) demonstrated that raloxifene was as effective as tamoxifen in reducing the risk of invasive breast cancer (IBC) in postmenopausal women and had lower risks of thromboembolic events, endometrial cancer, and cataracts but had a nonstatistically significant higher risk of noninvasive breast cancer. There is a need to summarize the risks and benefits of these agents.